Table 1.
Patient characteristics
| First consolidation |
Relapsed | |
|---|---|---|
| N | 118 | 58 |
| Median age (range) | 58 (37–74) | 56 (37–68) |
| Male | 58% | 64% |
| Durie–Salmon stage at diagnosis | ||
| 1A | 0 | 12% |
| 1B | 0 | 0 |
| 2A | 36% | 33% |
| 2B | 3% | 0 |
| 3A | 46% | 43% |
| 3B | 13% | 12% |
| Unknown | 2% | 0 |
| End organ damage at diagnosis | ||
| Calcium > 12 mg/dL | 9% | NA |
| Creatinine ≥ 2mg/dL | 14% | NA |
| Hb 8.5–10 g/dL | 18% | NA |
| Hb <8.5 g/dL | 19% | NA |
| Lytic lesions (not extensive) | 44% | NA |
| Advanced lytic lesions | 26% | NA |
| Isotype | ||
| IgA | 29% | 14% |
| IgG κ | 32% | 50% |
| IgG λ | 17% | 21% |
| Light chain only | 18% | 10% |
| IgD | 1% | 0 |
| Non-secretory | 3% | 5% |
| Prior regimens | ||
| Median no. (range) | 1 (1–2) | 2 (1–4) |
| VAD | 79% | 79% |
| Alkylator based | 10% | 50% |
| Thalidomide | 34% | 64% |
| Bortezomib | 0 | 31% |
| Lenalidomide | 0 | 0 |
| Median years diagnosis to BMT (range) |
0.86 (0.33–2.8) | 1.71 (0.45–16.8) |
Abbreviations: NA = not applicable; VAD = VCR, doxorubicin, dexamethasone.
Characteristics of patients transplanted in first consolidation or relapse.